News Conference News ESC 2020 VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban L.A. McKeown September 03, 2020
News Daily News High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention Michael O'Riordan August 11, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
News Daily News Rivaroxaban May Yet Protect After a Hospital Stay: MARINER Caitlin E. Cox June 25, 2020
News Daily News More Evidence of Lower Fracture Risk With DOACs Versus Warfarin Todd Neale May 19, 2020
News Daily News How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions Michael O'Riordan April 22, 2020
News Conference News ACC 2020 New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy L.A. McKeown April 02, 2020
Presentation ACC 2020 VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel Presenter: William Hiatt March 29, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Daily News COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients Todd Neale March 27, 2020
News Conference News ACC 2020 Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds Todd Neale March 25, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020